OGN or DOCS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now?
Organon (OGN) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Organon (OGN) closed at $10.19, indicating a +1.49% shift from the previous trading day.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon & Co: Cost Takeout Catalysts, Initiate Strong Buy
Initiate Strong Buy on Organon & Co. with $26.4 PT, driven by cost savings, Nexplanon momentum, and biosimilars diversification offsetting Established Brands LOE. Forecasted EPS of $4.00 (FY25; +20.1% Y/Y) and $4.40 (FY26; +10.0%), well above consensus, supported by operational leverage and dividend cut for deleveraging. Transformational cost savings of >$200M by FY25 and $275M by FY26, driving margin expansion and multi-year EPS acceleration.
Organon: Management Slashes Dividend - This Feels Disastrous
Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue shrinkage is primarily due to declining sales in its Established Brands division, exacerbated by the patent expiry of key drugs. Management's rationale for cutting the dividend to manage debt and pursue M&A opportunities appears flawed, as it fails to address core financial issues.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Why The Low Payout Ratio Did Not Stop The Dividend Cut For Organon
Organon boasted of a sub-33% dividend payout ratio.
Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon & Co. (OGN) Q1 2025 Earnings Call Transcript
Organon & Co. (NYSE:OGN ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matt Walsh - CFO Juan Camilo Arjona Ferreira - Head of R&D Conference Call Participants David Amsellem - Piper Sandler Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan Umer Raffat - Evercore ISI Bhavin Patel - Bank of America Operator Hello, and welcome to the Organon First Quarter 2025 Earnings Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Jennifer Halchak, Vice President, Investor Relations.
Organon (OGN) Q1 Earnings Surpass Estimates
Organon (OGN) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $1.22 per share a year ago.
Countdown to Organon (OGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Organon (OGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
